DETERMINANTS OF SWITCHING TO TWO-DRUG COMBINATIONS WITH HIV-RNA ≤50 COPIES/ML IN A COHORT OF HIV-INFECTED INDIVIDUALS SEEN FOR CARE IN ITALY

A. Cozzi-Lepri , H. Diaz-Cuervo, N. Gianotti , G. Lapadula , A. De Luca , F. Maggiolo , S. Rusconi , N. Bobbio , V. Esposito , M.C. Moioli , G. Madeddu , A. Antinori , A. d'Arminio Monforte for the Icona Foundation Study Group

University College London, Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL, LONDON, United Kingdom, San Raffaele Hospital, Milano, Italy AO "San Gerardo" di Monza, Monza, Italy, University of Siena, Siena, Italy, AO Papa Giovanni XXIII, Bergamo, Italy, Sacco Hospital, Milano, Italy, Ospedali Galliera, Genova, Italy, AORN Ospedali dei Colli, Napoli, Italy, Niguarda Hospital, Milano, Italy, Sassari University, Sassari, Italy, INMI Spallanzani, Roma, Italy, S.Paolo Hospital, Milano, Italy

P068

BACKGROUND

- Although some two-drug combinations (2DC) are now recommended as alternative in guidelines for use in specific contexts, there is little data documenting how frequently and in which patients these regimens are used in clinical practice in people with a viral load (VL)≤50 copies/mL

AIMS

- To describe the main characteristics of a population of HIV-infected persons who switched from triple cART regimen to another triple combination (TT) or to a dolutegravir(DTG)-based or PI-based 2DC with a viral load(VL)≤50 copies/mL, regardless of the reason for switching.
- To identify factors associated with the probability of switching to each of the 2DC regimens, as opposed to a standard switch to triple therapy.

STUDY DESIGN AND METHODS

- The study includes data of HIV patients in the Icona Foundation Study cohort who switched to TT or to a DTG- or PI-based 2DC. Index date for this cross-sectional analysis was the date of first undergoing a therapy switch with the specific regimens of interest after achieving VL≤50 copies/mL over the period Jan 2004-Jun 2018.

- Only three type of switches were considered (first time ever occurring):
  i) a switch to another standard TT;
  ii) a switch to a DTG-based 2DC (including 3TC+DTG or RPV+DTG), and
  iii) a switch to a PI-based 2DC (including 3TC+DRV+r or cobicistat, 3TC+LPV+r and 3TC+ATV±r).

- Chi-square test was used to compare categorical factors and Kruskal-Wallis test to compare medians across the three switch groups.

- Multinomial logistic regression was used to identify factors associated with the probability of switching to DTG-, PI-2DC vs. TT. For factors with global p ≤0.5 specific contrasts (DTG-2DC vs. TT and PI-2DC vs. TT) were also calculated.

- Framingham CHD score and D.A.D. CKD scores were evaluated in the model. Therefore, all factors used to calculate such scores were not individually included.

- Potential confounding mechanisms were investigated.

RESULTS

- A total of 3,859 switches were included. Four percent switched to DTG-2DC (3% 3TC+DTG, 1% RPV+DTG) and 7% to PI-2DC (3% 3TC+DRV+r or cobi, 1% 3TC+LPV+r, 3% 3TC+ATV±r).
- Median age of patients was 43 years, baseline CD4 571 cells/mm^3, 21% female, 14% of foreign origins.
- In the unadjusted analysis (Table 1), compared to patients switched to TT those on DTG-2DC and PI-2DC were older, had longer exposure to ART, had higher CD4 at switch, had switched more recently, had higher cardiovascular disease and CHD risk, had higher ESRD and higher CKD risk.
- In the unadjusted analysis people with an history of >3 virological failures before baseline appeared to have greater odds of switching to PI-based 2DC as opposed to TT (unadjusted odds ratio (OR)=1.76; p=0.01). However, this association was confounded by total duration of exposure to ART before baseline (adjusted (aOR)=0.61, p=0.06).
- In the adjusted analysis (Table 2), compared to TT, switches to 2DC occurred more frequently in recent years, older participants, those with higher CD4 and still free from AIDS, those with less extensive history of virological failure before baseline and higher estimated risk of renal disease.
- For all these factors, the strength of the association was similar regardless of the type of 2DC regimen (Table 2).

Table 1 – Main characteristics of participants

Characteristics	Triple N= 3380	DTG-based* N= 191	PIr-based& N= 288	p-value
Gender, Female	22%	23%	22%	0.833
Age, Median (IQR), years	43 (36, 49)	49 (40, 57)	48 (41, 54)	<.001
>50, n(%)	23%	47%	39%	
Mode of HIV transmission				0.029
Heterosexual contacts	41%	42%	41%	
PWID	12%	7%	15%	
MSM	40%	48%	38%	
Other/unknown	7%	3%	7%	
Origin, Foreign	14%	8%	13%	0.082
HBsAg+, n(%)	5%	5%	2%	0.067
HCVAb+, n(%)	21%	23%	29%	0.017
CD4 count, cells/mmc				<.001
350+	81%	92%	90%	
201-350	13%	6%	9%	
0-200	6%	3%	1%	
Nadir CD4 count, cells/mmc				0.054
350+	30%	38%	30%	
201-350	36%	37%	34%	
0-200	35%	25%	36%	
Year of switch, >2010	68%	100%	94%	<.001
Smoking				0.610
No	50%	53%	49%	
Yes	41%	37%	40%	
Unknown	9%	9%	11%	
CHD Framingham score, Median (IQR)	9 (5, 17)	12 (7, 27)	14 (8, 26)	<.001
Low	43%	34%	31%	
Moderate	23%	23%	29%	
High	15%	27%	28%	
Unknown	20%	17%	13%	
Exposure to ART, Median (IQR),years	3 (1, 5)	4 (2, 10)	4 (2, 9)	<.001
>5, n(%)	23%	37%	43%	
Number of ARVs previously failed, Median (IQR)#	3 (3, 4)	3 (2, 5)	3 (2, 5)	0.043
>3, n(%)	5%	5%	8%	
Number of ARVs previously used, Median (IQR)	3 (2, 4)	4 (2, 6)	4 (3, 7)	<.001
>3, n(%)	27%	58%	61%	
Hypertension	56%	54%	63%	0.054
AIDS	14%)	9%	12%	0.059
Diabetes	3%	6%	4%	0.083
Cardiovascular disease	14%	24%	24%	<.001
ESLD	0.1%	1%	1%	0.087
ESRD	3%	15%	10%	<.001
eGFR, CKD-Epi				<.001
90+	65%	38%	43%	
60-90	32%	47%	47%	
<60	3%	15%	10%	
CKD D.A.D. score				<.001
Low	47%	28%	30%	
Moderate	27%	24%	20%	
High	26%	48%	50%	

*3TC-DTG or RPV-DTG
&3TC-DRV-cobi or 3TC-LPV-r or 3TC-ATV
#in those with >1 failure

Table 2 – Adjusted OR of switching to 2DC regimens instead of another triple from fitting a multinomial logistic regression analysis

Characteristics	DTG-based*	PI-based&	p-value
Origin Foreign vs. Italian	0.60 (0.34, 1.05)	1.20 (0.80, 1.80)	0.110
HBsAg+ vs. HBsAg-neg, n(%)	0.93 (0.43, 1.97)	0.37 (0.15, 0.92)	0.101
CD4 count, cells/mmc			0.006
201-350 vs. 350+	0.49 (0.25, 0.96)	0.57 (0.36, 0.93)	
0-200 vs. 350+	0.56 (0.21, 1.53)	0.27 (0.10, 0.76)	
p-value**	0.018	0.002	
Year of switch, per year more recent	1.87 (1.66, 2.10)	1.16 (1.11, 1.21)	<.001
p-value**	<.001	<.001	
Exposure to ART, per 5 years longer	0.60 (0.34, 1.05)	1.20 (0.80, 1.80)	0.110
Number of ARVs previously failed, per 3 additional	0.65 (0.54, 0.77)	0.68 (0.60, 0.77)	<.001
p-value**	<.001	<.001	
Previous CVD (Yes vs. No)	1.22 (0.79, 1.90)	1.00 (0.70, 1.43)	0.656
AIDS (Yes vs. No)	0.51 (0.29, 0.91)	0.68 (0.45, 1.03)	0.025
p-value**	0.016	0.041	
Framingham CHD score			0.629
Moderate vs. Low	0.79 (0.50, 1.24)	1.23 (0.86, 1.75)	
High vs. Low	0.87 (0.52, 1.44)	1.28 (0.85, 1.94)	
N/A vs. Low	1.12 (0.70, 1.78)	1.04 (0.68, 1.57)	
p-value**	0.890	0.690	
DAD CKD score			<.001
Moderate vs. Low	1.43 (0.92, 2.22)	0.99 (0.68, 1.45)	
High vs. Low	2.06 (1.33, 3.20)	2.01 (1.41, 2.86)	
p-value**	0.004	<.001	

*3TC-DTG or RPV-DTG
&3TC-DRV-cobi or 3TC-LPV-r or 3TC-ATV
$Adjusted for all factors shown in table
**Contrasts Chi-square p-values

CONCLUSIONS

Although switches to 2DC occurred more frequently in recent years, over 80% of participants with a VL ≤50 copies/mL in our analysis switched to another standard TT. In our study population of people seen for care in Italy, patients appear to be selected for 2DC strategies based on older age, less evidence of previous virological failure, more stable HIV disease and higher risk for renal complications. Further research is necessary to prospectively assess the virological and clinical outcomes of these strategies.

Acknowledgments

ICONA Foundation Study Group

BOARD OF DIRECTORS: *A d'Arminio Monforte (President), A Antinori (Vice-President), M Andreoni, A Castagna, F Castelli, R Cauda, G Di Perri, M Galli, R Iardino, G Ippolito, A Lazzarin, GC Marchetti, G Rezza, F von Schloesser, P Viale.*
SCIENTIFIC SECRETARY: *A d'Arminio Monforte, A Antinori, A Castagna, F Ceccherini-Silberstein, A Cozzi-Lepri, E Girardi, S Lo Caputo, C Mussini, M Puoti, CF Perno.*
STEERING COMMITTEE: *A Antinori, F Bai, C Balotta, A Bandera, S Bonora, M Borderi, A Calcagno, A Capetti, MR Capobianchi, A Castagna, F Ceccherini-Silberstein, S Cicalini, A Cingolani, P Cinque, A Cozzi-Lepri, A d'Arminio Monforte, A De Luca, A Di Biagio, E Girardi, N Gianotti, A Gori, G Guaraldi, G Lapadula, M Lichtner, S Lo Caputo, G Madeddu, F Maggiolo, G Marchetti, L Monno, C Mussini, S Nozza, CF Perno, C Pinnetti, M Puoti, E Quiros Roldan, R Rossotti, S Rusconi, MM Santoro, A Saracino, L Sarmati.*
STATISTICAL AND MONITORING TEAM: *A Cozzi-Lepri, I Fanti, L Galli, P Lorenzini, A Rodano', M Macchia, A Tavelli.*
BIOLOGICAL BANK INMI: *F Carletti, S Carrara, A Di Caro, S Graziano, F Petroni, G Prota, S Truffa.*
PARTICIPATING PHYSICIANS AND CENTERS: *Italy A Giacometti, A Costantini, V Barocci (Ancona); G Angarano, L Monno, C Fabrizio (Bari); F Maggiolo, C Suardi (Bergamo); P Viale, V Donati, G Verucchi (Bologna); F Castelnuovo, C Minardi, E Quiros Roldan (Brescia); B Menzaghi, C Abeli (Busto Arsizio); B Cacopardo, B Celesia (Catania); J Vecchiet, K Falasca (Chieti); A Pan, S Lorenzotti (Cremona); L Sighinolfi, D Segala (Ferrara); P Blanc, F Vichi (Firenze); G Cassola, C Viscoli, A Alessandrini, N Bobbio, G Mazzarello (Genova); M Lichtner, S Vita, (Latina); P Bonfanti, C Molteni (Lecco); A Chiodera, P Milini (Macerata); G Nunnari, G Pellicanò (Messina); A d'Arminio Monforte, M Galli, A Lazzarin, G Rizzardini, M Puoti, A Castagna, S Cannizzo, MC Moioli, R Piolini, AL Ridolfo, S Salpietro, C Tincati, (Milano); C Mussini, C Puzzolante (Modena); C Migliorino, G Lapadula (Monza); V Sangiovanni, G Borgia, V Esposito, F Di Martino, I Gentile, L Maddaloni (Napoli); AM Cattelan, S Marinello (Padova); A Cascio, C Colomba (Palermo); F Baldelli, E Schiaroli (Perugia); G Parruti, F Sozio (Pescara); G Magnani, MA Ursitti (Reggio Emilia); M Andreoni, A Antinori, R Cauda, A Cristaudo, V Vullo, R Acinapura, G Baldin, M Capozzi, A Mondi, A Cingolani, M Rivano Capparucia, G Iaiani, A Latini, R Gagliardini, MM Plazzi, S Savinelli, A Vergori (Roma); M Cecchetto, F Viviani (Rovigo); G Madeddu, P Bagella (Sassari); A De Luca, B Rossetti (Siena); A Franco, R Fontana Del Vecchio (Siracusa); D Francisci, C Di Giuli (Terni); P Caramello, G Di Perri, S Bonora, GC Orofino, M Sciandra (Torino); M Bassetti, A Londero (Udine); G Pellizzer, V Manfrin (Vicenza); G Starnini, A Ialungo (Viterbo).*

References

1: Madeddu G, et al. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL. Infection. 2017 Aug;45(4):521-528.
2. Jabłonowska E, Pulik P, Kalinowska A, Gąsiorowski J, Parczewski M, Bociąga-Jasik M, Pulik Ł, Siwak E, Wójcik K. Efficacy and safety of nucleoside-sparing regimen based on raltegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. J Med Virol. 2017

Funding

ICONA Foundation is supported by unrestricted grants from BMS, Gilead Sciences, Janssen, MSD and ViiV Healthcare.

The analysis of this particular study have been conducted thank to a specific add-on unconditional sponsorship from Gilead Sciences.

Contact Information

Alessandro Cozzi-Lepri
Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME) Institute for Global Health UCL
Rowland Hill St London NW3 2PF UK
Tel.: 0207 794 0500 ext. 34689
Email: a.cozzi-lepri@ucl.ac.uk